Though the full impact of a recent federal court ruling is unclear, doctors can expect more off-label drug use information from drug manufacturers. Washington — Eli Lilly announced this month that it would direct its sales representatives to market its osteoporosis drug, Evista (raloxifene), as a breast cancer prevention agent.This step was noteworthy for two